Fundraising Fox
Inimmune
Whitefish, US · Founded 2016 · 36 employees on LinkedIn · 1 known investors
Find your way into Inimmune
439 people in our graph share verified history with the Inimmune team — schools, employers, funds. One of them is your warm intro.
Avery Sonnenbergunlockedknows David Burkhart · together at Inimmune (overlapped)
knows the team · via University of Montana
×3knows the team · via GlaxoSmithKline
×7knows the team · via GSK
Inimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Founders & leadership
Inimmune was founded in 2016 by Jay Evans, David Burkhart, Helene Bazin-Lee, and Kendal Ryter.
JE
Jay EvansJay Evans is Chief Scientific and Strategy Officer of Inimmune, a clinical-stage biotech company developing immunotherapies for allergic, infectious, and autoimmune diseases. He holds a Ph.D. in Molecular and Cellular Biology from Oregon State University, completed postdoctoral fellowships at University of Texas Southwestern Medical Center and St. Jude Children's Research Hospital, and spent 15 years in vaccine and immunotherapy development at GlaxoSmithKline Vaccines and its predecessor Corixa Corporation.
DB
David BurkhartDavid Burkhart leads Inimmune, a clinical-stage biotech company developing immunotherapies and vaccines. He has 17 years of experience in the pharmaceutical industry with expertise in immunotherapeutics, vaccine development, drug delivery, bioconjugation, medicinal chemistry, and process development.
KR
Kendal RyterKendal Ryter holds a PhD in organic chemistry from Montana State University-Bozeman and has worked in vaccine development and pharmaceutical research, including experience at GSK. He is a co-founder of Inimmune and holds a faculty appointment at the University of Montana.
Investors · 1
Two Bear Capital✓ confirmed by InimmuneWhitefish · $3M – $10M
How we know: Two Bear Capital's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountfirst round of fundingJul 2020Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 7
Inmune BioINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immune-Onc TherapeuticsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
InfinimmuneInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
ImmunaiImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Immunomic TherapeuticsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies working in the same space as Inimmune.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $592.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $176.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Inimmune do?
- Inimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
- Who founded Inimmune?
- Inimmune was founded by Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter in 2016.
- Who are Inimmune's investors?
- Inimmune's investors include Two Bear Capital.
- Where is Inimmune headquartered?
- Inimmune is headquartered in Whitefish, US.